Industry News

- Read more about AstraZeneca to harness power of the Secretome and develop next-generation biologics in collaboration with new Wallenberg Centre for Protein Research
AstraZeneca and its global biologics research and development arm, MedImmune, announced a three-year collaboration with the newly established Wallenberg Centre for Protein Research (WCPR). The collaboration aims to develop new technologies for biologics production and to identify new targets for disease research in the ground-breaking area of the Secretome - research into all proteins that are secreted by a cell or that are exposed to the outside of the cell from within the cell membrane.
- Read more about AcelRx Pharmaceuticals conducts Pre-NDA Meeting with USFDA for ARX-04
AcelRx Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the development and commercialization of innovative therapies designed for the treatment of acute pain, reported on the outcome of the ARX-04 (sufentanil sublingual tablet, 30 mcg) pre-NDA meeting held recently with the U.S. Food and Drug Administration (FDA).
- Read more about UBM India Pharma Awards received by top Pharma companies
The UBM India Pharma Awards 2015 held on 30th November, 2015 in, Mumbai, celebrated excellence and recognized contribution of Indian Pharmaceutical Companies. The 3^rd Edition of Annual India Pharma Awards in association with TAKE solutions provided an opportunity for the companies to showcase their innovations and accomplishments in the sector.
- Read more about FDA approves first emergency treatment for overdose of certain types of chemotherapy
The U.S. Food and Drug Administration approved Vistogard (uridine triacetate) for the emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or capecitabine, or who develop certain severe or life-threatening toxicities within four days of receiving these cancer treatments.
- Read more about FDA approves new oral therapy to treat ALK-positive lung cancer
The U.S. Food and Drug Administration approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Xalkori (crizotinib).
- Read more about Sun Pharma divestmented US manufacturing unit
Sun Pharma's manufacturing consolidation in the US, one of its wholly owned subsidiaries has entered into an agreement with Nostrum Laboratories Inc. (Nostrum) for the divestment of the Bryan (Ohio) unit in the US.
- Read more about Nepal seized Dabur products due to expiry dates issue
Nepalese authorities on Sunday confiscated 90 cargo containers loaded with products of Dabur Nepal bound for India from the Sirsiya dry port in Birgunj district.
- Read more about Natco Pharma settled patent infringement with Gilead Sciences & others
Natco Pharma and Alvogen have settled the patent infringement suit filed by Gilead Sciences, Hoffmann-La Roche, F. Hoffmann-La Roche Ltd. and Genentech Inc. against them in New Jersey District Court.
- Read more about 300 million child-friendly antimalarial treatments supplied without profit by Novartis
- Coartem® Dispersible*, the first WHO prequalified pediatric antimalarial treatment, has become the standard of care in over 30 malaria-endemic countries
- Since 2009, Novartis has supplied 300 million Coartem® Dispersible treatments without profit, mostly to the public sector, to treat children suffering from malaria
- Together with other innovations, Coartem® Dispersible contributed to reduce the malaria death rate by 71% for children under the age of 5 years
- Read more about Rhizen Pharmaceuticals entered license agreement with Novartis
Rhizen Pharmaceuticals have entered into an exclusive, worldwide license agreement, with Novartis for the development and commercialization of Rhizen’s, inhaled dual PI3K - delta gamma inhibitor and its closely related compounds for various indications.